mazindol has been researched along with Sleep Initiation and Maintenance Disorders in 2 studies
Mazindol: Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Sleep Initiation and Maintenance Disorders: Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enzi, G | 1 |
| Baritussio, A | 1 |
| Marchiori, E | 1 |
| Crepaldi, G | 1 |
| Sedgwick, JP | 1 |
2 trials available for mazindol and Sleep Initiation and Maintenance Disorders
| Article | Year |
|---|---|
Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity.
Topics: Adolescent; Adult; Anxiety; Diet, Reducing; Drug Evaluation; Glucose Tolerance Test; Humans; Indoles | 1976 |
Maziniol in the treatment of obesity.
Topics: Body Weight; Clinical Trials as Topic; Constipation; Humans; Indoles; Mazindol; Obesity; Placebos; S | 1975 |